Fig. 6

BC31M4 efficiently promotes the adaptive immune responses against tumors in syngeneic mouse models and promotes the development of immune memory. a Schematic diagram of tumor inoculation and treatment. C57-hCD47/hSIRPα mice were s.c. inoculated with E.G7-hCD47 cells on the right lower flank. Antibodies or PBS were i.p. injected, OT-I T cells were i.v. transfused. b The tumor growth of mice treated as in (a); Treatment-related-death mice were excluded from summary statistics. c Survival of mice in (b). d Schematic diagram of tumor inoculation and treatment. e The tumor growth of mice treated as in (d). f Survival of mice in (e). g Schematic diagram of tumor rechallenge. C57-hCD47/hSIRPα mice were initially inoculated and treated as in (a), cured mice were rechallenged with E.G7-hCD47 or EL4-hCD47 cells about 140 days after the initial tumor inoculation. The rechallenged tumor cells were s.c. inoculated on the left lower flank. h, i Tumor growth in rechallenged mice is shown individually. Age-matched, naïve, C57-hCD47/hSIRPα mice were included as controls. Proportions of tumor free mice are indicated. n, number of mice. Antibodies used in (a–g) are mIgG2a isotype unless otherwise noted